Database : MEDLINE
Search on : Hepatic and Veno-Occlusive and Disease [Words]
References found : 1656 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 166 go to page                         

  1 / 1656 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524571
[Au] Autor:Dusemund B; Nowak N; Sommerfeld C; Lindtner O; Schäfer B; Lampen A
[Ad] Address:Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 10, 10589 Berlin, Germany. Electronic address: Birgit.Dusemund@bfr.bund.de.
[Ti] Title:Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin.
[So] Source:Food Chem Toxicol;, 2018 Mar 07.
[Is] ISSN:1873-6351
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Acute liver toxicity, specifically in the form of hepatic veno-occlusive disease (HVOD), is known from reports on human poisonings following ingestions of 1,2-unsaturated pyrrolizidine alkaloids (PAs) containing herbs. Recently PA exposure via common foods contaminated via PA-producing plants raised concern, especially regarding the potential of genotoxicity and carcinogenicity. The health risks related to the estimated exposures to PAs from food were assessed. With respect to common foods, herbal teas and teas are the main sources through which consumers can be exposed to PAs. For high long-term consumption of these foods a possible health concern has been revealed in the assessment of chronic risks referring to a BMDL of 237 µg/kg bw per day recently established by EFSA based on model averaging for data on riddelliine. However, acute health damage from acute or short-term intake of PAs via common food is considered to be unlikely. Food supplements on the basis of PA-producing plants may significantly contribute to PA exposures and their intake is associated with risks of acute and chronic toxicity. However, no health risks have to be expected from the consumption of food supplements based on oil-based preparations of PA-producing plants, which were described to be free of PAs.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 1656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29191686
[Au] Autor:Yang S; Wu J; Lei S
[Ad] Address:Department of Radiology, The Second XiangYa Hospital, Central South University, Changsha, Hunan 410011, China. Electronic address: yangsong611y@qq.com.
[Ti] Title:CT Features of Hepatic Veno-occlusive Disease: A Meta-analysis.
[So] Source:Acad Radiol;25(3):328-337, 2018 Mar.
[Is] ISSN:1878-4046
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE AND OBJECTIVE: The computed tomography (CT) features of hepatic veno-occlusive disease (HVOD) could play a role in its diagnosis. We aimed to perform a meta-analysis of studies examining the CT features of HVOD. METHODS: Relevant studies published up to May 3, 2017 were searched in major electronic databases. The extracted data included the proportion of various CT features in patients with HVOD. The meta-analysis was conducted using R 3.3.3 with the "meta" package. RESULTS: Eleven studies were included. The studies involved 326 patients with a mean age range of 50.2-58.9 years, and the proportion of female patients ranged from 20% to 57.5%. The meta-analysis showed the pooled proportion of CT features: hepatic parenchyma with heterogeneous hypoattenuation (81.05%, 95% confidence interval [CI]: 56.97%-93.25%), patchy enhancement in the portal venous phase (87.09%, 95% CI: 75.15%-93.77%) with or without a narrow or invisible hepatic vein (71.02% 95% CI: 42.09%-89.20%), gallbladder wall edema (65.51%, 95% CI: 28.98%-89.84%), and patchy heterogeneous enhancement in the arterial phase (44.36%, 95% CI: 29.98%-59.76%) with or without slightly enlarged hepatic artery (56.61%, 95% CI: 40.62%-71.33%). CONCLUSION: Hepatic parenchyma with heterogeneous hypoattenuation and patchy enhancement with or without narrowing or an invisible hepatic vein in the portal venous or equilibrium phase may be the most important CT feature for diagnosing HVOD.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:In-Data-Review

  3 / 1656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29477779
[Au] Autor:Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
[Ad] Address:Hematology and Cellular Therapy Service, Saint Antoine Hospital, AP-HP, Paris, France.
[Ti] Title:Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: a Single Center Experience Study.
[So] Source:Biol Blood Marrow Transplant;, 2018 Feb 22.
[Is] ISSN:1523-6536
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD) is a serious complication after hematopoietic stem cell transplantation (HSCT). SOS/VOD usually occurs within 3 weeks of HSCT but the 2016 EBMT diagnosis criteria have been revised to include late forms. Prophylactic use of defibrotide is recommended in the pediatric setting but its value remains uncertain in the adult population. We report here a single center series of 63 adult patients considered at high risk of SOS/VOD, receiving defibrotide prophylaxis in combination with ursodeoxycholic acid between May 2012 and August 2016. The median duration of defibrotide therapy was 23 days. Bleeding occurred in 14 (21.5%) patients. Defibrotide prophylaxis was discontinued in 7 (10.8%) patients: 4 cases (6.3%) due to bleeding and 3 cases (4.6%) because of the need for antithrombotic therapy. Overall, SOS/VOD occurred in 4 cases (6.3%), within 21 days following HSCT (day 13 and 14) in two cases, and late-onset SOS/VOD (day 57 and 58) in the other two cases. SOS/VOD was moderate in one case, very severe in 3 cases with 2 deaths related to SOS/VOD. Cumulative incidence of grade II-IV acute graft-versus-host disease and transplant-associated thrombotic microangiopathy were 22.2% and 3.2%, respectively. With a median follow up of 31 months (range, 10.7-60.3), the 2-year overall survival, progression free survival, incidence of relapse, and non-relapse mortality were 56.5%, 49%, 28.7%, and 22.3%, respectively. In our experience, defibrotide prophylaxis is associated with a low incidence of SOS/VOD following allogeneic HSCT in a high-risk adult population with an acceptable safety profile.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180225
[Lr] Last revision date:180225
[St] Status:Publisher

  4 / 1656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29301447
[Au] Autor:Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
[Ad] Address:a Hematologic Oncology , Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute , Boston , MA , USA.
[Ti] Title:Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
[So] Source:Expert Rev Clin Pharmacol;11(2):113-124, 2018 Feb.
[Is] ISSN:1751-2441
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is an unpredictable condition associated with endothelial-cell damage due to conditioning for hematopoietic stem-cell transplantation (HSCT) or chemotherapy without HSCT. Mortality in patients with VOD/SOS and multi-organ dysfunction (MOD) may be >80%. Areas covered: Defibrotide is the only approved drug for the treatment of severe hepatic VOD/SOS after HSCT in the European Union and hepatic VOD/SOS with renal or pulmonary dysfunction in the United States. Its efficacy in patients with VOD/SOS with MOD post-HSCT was demonstrated in a clinical-trial program that included a historically controlled treatment study, a phase 2 trial, and a large T-IND expanded-access program that also included patients without MOD and who received chemotherapy without HSCT. Expert commentary: Defibrotide appears to protect endothelial cells and restore the thrombolytic-fibrinolytic balance. It addresses a significant clinical need and has demonstrated favorable Day +100 survival and overall adverse-event rates that seem similar to control groups receiving supportive care alone. Currently, defibrotide is under investigation for the prevention of VOD/SOS in high-risk pediatric and adult patients.
[Mh] MeSH terms primary: Fibrinolytic Agents/therapeutic use
Hepatic Veno-Occlusive Disease/drug therapy
Polydeoxyribonucleotides/therapeutic use
[Mh] MeSH terms secundary: Antineoplastic Agents/administration & dosage
Antineoplastic Agents/adverse effects
Endothelial Cells/pathology
Hematopoietic Stem Cell Transplantation/adverse effects
Hepatic Veno-Occlusive Disease/etiology
Hepatic Veno-Occlusive Disease/mortality
Humans
Severity of Illness Index
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (Fibrinolytic Agents); 0 (Polydeoxyribonucleotides); 438HCF2X0M (defibrotide)
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:IM
[Da] Date of entry for processing:180106
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2018.1421943

  5 / 1656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28460209
[Au] Autor:Bagal B; Chandrasekharan A; Chougle A; Khattry N
[Ad] Address:Department of Medical Oncology, Tata Memorial Center, Mumbai, India. Electronic address: bagalbp@gmail.com.
[Ti] Title:Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation.
[So] Source:Hematol Oncol Stem Cell Ther;11(1):47-51, 2018 Mar.
[Is] ISSN:1658-3876
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE/BACKGROUND: Hepatic veno-occlusive disease (VOD) is well recognized potentially serious regimen-related toxicity seen after stem cell transplantation. Severe VOD is associated with poor long-term outcomes with very high mortality. Besides supportive care, only defibrotide has been found to be effective in the management of VOD. The recommended dose of defibrotide is 25mg/kg/d but there has been no classical dose finding study done for this drug. A higher dose of defibrotide is associated with increased risk of bleeding and this drug is prohibitively expensive. We report our experience of using fixed low dose of defibrotide in patients with VOD. METHODS: We retrospectively evaluated 511 patients who underwent stem cell transplant at our center from November 2007 and December 2015. All patients received ursodeoxycholic acid as VOD prophylaxis. Modified Seattle criterion was used for diagnosis and severity grading of VOD. Patients developing VOD were initially treated with furosemide and adequate analgesia. Defibrotide was started within 12 to 24 hours of diagnosis of VOD. All adult patients received defibrotide at a fixed dose of 200mg twice daily while two children were given dose of 100mg and 50mg twice daily. RESULTS: Nine (1.7%) of our patients developed VOD. Daily dose of defibrotide ranged from 5mg/kg/d to 20mg/kg/d till resolution of VOD. All patients had complete resolution of VOD. None of our patients required ventilator support or dialysis. No episodes of bleeding were observed. No dose response relationship was observed between defibrotide dose and time to resolution of VOD. CONCLUSION: Low fixed dose defibrotide initiated early seems to be effective and safe in treatment of VOD. This is relevant in a resource limited setting and warrants prospective evaluation.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1705
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[St] Status:In-Process

  6 / 1656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29350698
[Au] Autor:Ní Chonghaile M; Wolownik K
[Ad] Address:St. James's Hospital in Dublin.
[Ti] Title:Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Eelated to Hematopoietic Stem Cell Transplantation
.
[So] Source:Clin J Oncol Nurs;22(1):E7-E17, 2018 Feb 01.
[Is] ISSN:1538-067X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Sinusoidal obstruction syndrome (SOS), also called hepatic veno-occlusive disease (VOD), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) that affects about 1 in 7 patients undergoing this procedure. SOS/VOD is caused by the conditioning regimens administered prior to HSCT; in some cases, SOS/VOD results from chemotherapy alone. SOS/VOD usually develops within three weeks following HSCT; however, it can have later onset. 
. OBJECTIVES: Clearly understanding how SOS/VOD develops may support prompt detection and treatment when the condition arises.
. METHODS: Research on identification and management of SOS/VOD is summarized, and data from clinical trials are reviewed.
. FINDINGS: This article describes the syndrome, risk factors, signs and symptoms, and appropriate supportive care and treatment. The authors also offer some practical tips for detecting SOS/VOD and providing patient care, as well as the latest information on treating and preventing this condition.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180119
[Lr] Last revision date:180119
[St] Status:In-Data-Review
[do] DOI:10.1188/18.CJON.E7-E17

  7 / 1656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29278102
[Au] Autor:Mesini A; Cangemi G; Palmisani E; Dufour C; Castagnola E
[Ad] Address:a Infectious Diseases Division , University of Genoa (DISSAL) , Genoa , Italy.
[Ti] Title:Hepatic veno-occlusive disease during isavuconazole administration.
[So] Source:J Chemother;30(1):63-64, 2018 Feb.
[Is] ISSN:1973-9478
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180119
[Lr] Last revision date:180119
[St] Status:In-Data-Review
[do] DOI:10.1080/1120009X.2017.1418619

  8 / 1656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29301090
[Au] Autor:Al Adham EK; Hassan AI; Hazem MM; Shebl A
[Ad] Address:Egyptian Atomic Energy Authority, 68892, Radioisotopes , GIZA , GIZA, Egypt , 12311 ; saso_d35@yahoo.com.
[Ti] Title:Evaluation of Therapeutic Effect of Rice Husk Silica Combined with Platelets Derived Growth Factor in Hepatic Veno- Occlusive Disease.
[So] Source:Biochem Cell Biol;, 2018 Jan 04.
[Is] ISSN:1208-6002
[Cp] Country of publication:Canada
[La] Language:eng
[Ab] Abstract:Veno- occlusive disease is an important pattern of hepatotoxicity associated with antineoplastic drugs. The study aimed to investigate the possible therapeutic impact of rice husk silica (RHS) nanoparticles combined with a platelet-derived growth factor (PDGF) on the Veno-occlusive disease in liver (VOD) elicited by dactinomycin (DAC) in rats. Forty-eight male Sprague-Dawely rats were classified into six groups, 8 rats each. The first group served as control, the second, animals were infused by intraperitoneal injection with DAC (0.015 mg/kg; 1-3 days IP). The third group, rats were injected IP with DAC and then at 24 h followed the last dose of DAC received nano RHS incorporated with PDGF twice a week for four weeks. The fourth group, normal animals were injected with RHS. The fifth group normal rats were received with PDGF, and the sixth group normal rats were received nano RHS incorporated with PDGF. The results of this work showed that administration of nano RHS joined with PDGF significantly reversed the oxidative stress effects of DAC that was evidenced by decreasing in liver function. It could be concluded that the nano RHS combined with PDGF is useful in preventing of oxidative stress and hepatic Veno-occlusive induced by receiving chemotherapy (DAC).
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180104
[Lr] Last revision date:180104
[St] Status:Publisher
[do] DOI:10.1139/bcb-2017-0248

  9 / 1656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29294155
[Au] Autor:Park JE; Choi YH; Cheon JE; Kim WS; Kim IO; Ryu YJ; Kim YJ; Hong CR; Kang HJ
[Ad] Address:Department of Radiology, Seoul National University Children's Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.
[Ti] Title:Gallbladder wall oedema and ascites are independent predictors of progression to hepatic veno-occlusive disease for children with hematopoietic stem cell transplantation.
[So] Source:Eur Radiol;, 2018 Jan 02.
[Is] ISSN:1432-1084
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:OBJECTIVES: To evaluate the predictive value of ultrasonography in children with clinically suspicious hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation (HSCT). METHODS: Among 216 children who underwent HSCT, 70 also underwent colour Doppler ultrasonography. Of these, 59 had only one sign/symptom, which did not fulfil the diagnostic criteria (clinical suspicion of VOD) at that time. VOD was confirmed in 20 patients (VOD group), while 39 had other conditions (non-VOD group). The following findings were reviewed and compared between groups: left portal vein (peak velocity, direction), left hepatic artery (peak-systolic/end-diastolic velocities, resistive index), middle hepatic vein (peak velocity, phasicity), hepatomegaly, splenomegaly, gallbladder wall thickness, and ascites. RESULTS: The VOD group showed significantly higher reversed flow in portal vein (P = 0.011), peak systolic velocity of left hepatic artery (P = 0.028), monophasicity of middle hepatic vein (P = 0.015), hepatomegaly (P = 0.001), gallbladder wall thickness (P < 0.001), and ascites (P < 0.001). Multivariate regression revealed that gallbladder wall thickness and ascites (odds ratio = 35.370, 56.393) were associated with VOD. CONCLUSIONS: The presence of reversed flow in portal vein, increased peak systolic velocity of hepatic artery, monophasicity of hepatic vein, hepatomegaly, gallbladder wall thickness, and ascites were significantly associated with progression to VOD in children with clinically suspicious VOD after HSCT. KEY POINTS: • Ultrasonography with Doppler can help predict progression to VOD. • Gallbladder wall oedema and ascites are the independent predictors of progression to VOD.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180102
[Lr] Last revision date:180102
[St] Status:Publisher
[do] DOI:10.1007/s00330-017-5137-9

  10 / 1656 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28458594
[Au] Autor:You SH; Park BJ; Kim YH
[Ad] Address:Department of Radiology, Anam Hospital, Korea University College of Medicine, Seoul 02841, Korea.
[Ti] Title:Hepatic Lesions that Mimic Metastasis on Radiological Imaging during Chemotherapy for Gastrointestinal Malignancy: Recent Updates.
[So] Source:Korean J Radiol;18(3):413-426, 2017 May-Jun.
[Is] ISSN:2005-8330
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:During chemotherapy in patients with gastrointestinal malignancy, the hepatic lesions may occur as chemotherapy-induced lesions or tumor-associated lesions, with exceptions for infectious conditions and other incidentalomas. Focal hepatic lesions arising from chemotherapy-induced hepatopathies (such as chemotherapy-induced sinusoidal injury and steatosis) and tumor-associated eosinophilic abscess should be considered a mimicker of metastasis in patients with gastrointestinal malignancy. Accumulating evidence suggests that chemotherapy for gastrointestinal malignancy in the liver has roles in both the therapeutic effects for hepatic metastasis and injury to the non-tumor bearing hepatic parenchyma. In this article, we reviewed the updated concept of chemotherapy-induced hepatopathies and tumor-associated eosinophilic abscess in the liver, focusing on the pathological and radiological findings. Awareness of the causative chemo-agent, pathophysiology, and characteristic imaging findings of these mimickers is critical for accurate diagnosis and avoidance of unnecessary exposure of the patient to invasive tissue-based diagnosis and operations.
[Mh] MeSH terms primary: Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemical and Drug Induced Liver Injury/diagnostic imaging
Gastrointestinal Neoplasms/drug therapy
[Mh] MeSH terms secundary: Abscess/diagnostic imaging
Abscess/etiology
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Chemical and Drug Induced Liver Injury/etiology
Chemical and Drug Induced Liver Injury/pathology
Fatty Liver/diagnostic imaging
Fatty Liver/etiology
Fatty Liver/pathology
Gastrointestinal Neoplasms/pathology
Hepatic Veno-Occlusive Disease/diagnostic imaging
Hepatic Veno-Occlusive Disease/etiology
Hepatic Veno-Occlusive Disease/pathology
Humans
Liver Neoplasms/pathology
Liver Neoplasms/secondary
Magnetic Resonance Imaging
Tomography, X-Ray Computed
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1710
[Cu] Class update date: 180102
[Lr] Last revision date:180102
[Js] Journal subset:IM
[Da] Date of entry for processing:170502
[St] Status:MEDLINE
[do] DOI:10.3348/kjr.2017.18.3.413


page 1 of 166 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information